Literature DB >> 20110964

Translational research: Talking up translation.

Daniel Cressey.   

Abstract

Mesh：

Year:  2010        PMID： 20110964     DOI： 10.1038/463422a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  10 in total

1.  Synthetic lethality--a new direction in cancer-drug development.

Authors:  J Dirk Iglehart; Daniel P Silver
Journal:  N Engl J Med       Date:  2009-06-24       Impact factor: 91.245

2.  Identification of the breast cancer susceptibility gene BRCA2.

Authors:  R Wooster; G Bignell; J Lancaster; S Swift; S Seal; J Mangion; N Collins; S Gregory; C Gumbs; G Micklem
Journal:  Nature       Date:  1995 Dec 21-28       Impact factor: 49.962

3.  Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.

Authors:  R Wooster; S L Neuhausen; J Mangion; Y Quirk; D Ford; N Collins; K Nguyen; S Seal; T Tran; D Averill
Journal:  Science       Date:  1994-09-30       Impact factor: 47.728

4.  Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation.

Authors:  F Connor; D Bertwistle; P J Mee; G M Ross; S Swift; E Grigorieva; V L Tybulewicz; A Ashworth
Journal:  Nat Genet       Date:  1997-12       Impact factor: 38.330

5.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.

Authors:  Wataru Sakai; Elizabeth M Swisher; Beth Y Karlan; Mukesh K Agarwal; Jake Higgins; Cynthia Friedman; Emily Villegas; Céline Jacquemont; Daniel J Farrugia; Fergus J Couch; Nicole Urban; Toshiyasu Taniguchi
Journal:  Nature       Date:  2008-02-10       Impact factor: 49.962

6.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.

Authors:  Helen E Bryant; Niklas Schultz; Huw D Thomas; Kayan M Parker; Dan Flower; Elena Lopez; Suzanne Kyle; Mark Meuth; Nicola J Curtin; Thomas Helleday
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

7.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Authors:  Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono
Journal:  N Engl J Med       Date:  2009-06-24       Impact factor: 91.245

8.  Resistance to therapy caused by intragenic deletion in BRCA2.

Authors:  Stacey L Edwards; Rachel Brough; Christopher J Lord; Rachael Natrajan; Radost Vatcheva; Douglas A Levine; Jeff Boyd; Jorge S Reis-Filho; Alan Ashworth
Journal:  Nature       Date:  2008-02-10       Impact factor: 49.962

9.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Authors:  Hannah Farmer; Nuala McCabe; Christopher J Lord; Andrew N J Tutt; Damian A Johnson; Tobias B Richardson; Manuela Santarosa; Krystyna J Dillon; Ian Hickson; Charlotte Knights; Niall M B Martin; Stephen P Jackson; Graeme C M Smith; Alan Ashworth
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

10.  Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.

Authors:  Ana M Mendes-Pereira; Sarah A Martin; Rachel Brough; Afshan McCarthy; Jessica R Taylor; Jung-Sik Kim; Todd Waldman; Christopher J Lord; Alan Ashworth
Journal:  EMBO Mol Med       Date:  2009-09       Impact factor: 12.137
  10 in total
  2 in total

1.  The hope of progress.

Authors:  Miranda Robertson
Journal:  BMC Biol       Date:  2010-04-12       Impact factor: 7.431

Review 2.  Innovative solutions to novel drug development in mental health.

Authors:  T R Insel; V Voon; J S Nye; V J Brown; B M Altevogt; E T Bullmore; G M Goodwin; R J Howard; D J Kupfer; G Malloch; H M Marston; D J Nutt; T W Robbins; S M Stahl; M D Tricklebank; J H Williams; B J Sahakian
Journal:  Neurosci Biobehav Rev       Date:  2013-04-03       Impact factor: 8.989
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.